Pulmonx Corp (LUNG) company profile
Close on Nov 16, 2026Market cap $120.26MP/E –Yield –
About Pulmonx
Surgical & Medical Instruments & Apparatus, SIC 3841
The company is a commercial-stage medical technology business that develops and provides minimally invasive treatments for patients suffering from severe emphysema, a form of chronic obstructive pulmonary disease. Its core solution combines the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the LungTraX cloud-based analysis platform. In addition, the business manufactures the AeriSeal System, an investigational synthetic polymer foam designed to close collateral air channels in targeted lung lobes. The enterprise primarily sells its products directly to hospital customers, while focusing its sales and educational initiatives on interventional pulmonologists performing pulmonary procedures.
The business commercializes its products internationally across North America, Europe, and the Asia Pacific region, maintaining market access in countries such as the United States, Australia, Austria, Belgium, France, Germany, Japan, the Netherlands, South Korea, Switzerland, and the United Kingdom. It relies on a direct sales force in principal markets alongside distributor networks in smaller or emerging territories. The provided text does not state the location of the company's headquarters.
Summary of the business section of Pulmonx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pulmonx Corp
- Founded
- 1998
- Headquarters
- Redwood City, CA
- Address
- 700 Chesapeake Drive 94063
- Phone
- (650) 364-0400
- Website
- www.pulmonx.com
- Employees
- 296, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Francisco, California
Stock & identifiers
- Ticker
- LUNG
- Exchange
- Nasdaq
- IPO date
- Oct 1, 2020
- Shares outstanding
- 43M, Jul 31, 2026
- Public float
- $101.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1127537
- CUSIP
- 745848101
- ISIN
- US7458481014
- FIGI
- BBG000LZVJC9
- Share class FIGI
- BBG001T4HJ52
- LEI
- 549300WZMFR0ZK7RJY40
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Glendon E. French III | President and CEO, Director | 2,056,134 |
| Steven S. Williamson | PRESIDENT AND CEO, Director | 363,497 |
| David Aaron Lehman | General Counsel | 370,130 |
| Srikanth Radhakrishnan | Chief Science & Techn. Officer | 326,475 |
| Geoffrey Beran Rose | Chief Commercial Officer | 453,108 |
| Derrick Sung | COO and CFO | 1,335,319 |
| Mehul Joshi | Chief Financial Officer & PAO | 208,489 |
| Thomas William Burns | Director | 113,399 |
| Richard Ferrari | Director | 1,359,345 |
| Georgia Melenikiotou | Director | 139,714 |
| Dana G. Mead Jr. | Director | 143,790 |
| Daniel P. Florin | Director | 149,699 |
| Tiffany Sullivan | Director | 115,199 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Glendon EFrench | $3.54M | $2.93M | $2.22M | $3 | – |
| FY2025 Steven SWilliamson | $4.20M | $1.10M | $2.22M | $3 | – |
| FY2024 Glendon EFrench | $330.79K | -$2.38M | $2.36M | $10 | – |
| FY2024 Steve Williamson | $5.23M | $4.16M | $2.36M | $10 | – |
| FY2024 Steven SWilliamson | $5.23M | $4.16M | $2.36M | $10 | – |
| FY2023 | $5.80M | $8.21M | $2.42M | $18 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Glendon E. French Chief Executive Officer | $116.19K | – | $3.22M | – | – | $153.33K | $3.54M | +971% |
| Steven S. Williamson Former Chief Executive Officer | $493.46K | – | $2.26M | $752.38K | – | $691.18K | $4.20M | -20% |
| Derrick Sung Chief Operating Officer and Chief Financial Officer | $83.33K | $200.00K | $2.67M | – | – | $58 | $2.95M | – |
| Mehul Joshi Former Chief Financial Officer | $381.20K | – | $1.19M | – | – | $408.80K | $1.98M | -39% |
| David Lehman General Counsel | $472.40K | – | $1.19M | – | $43.79K | $452 | $1.71M | +15% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 1, 2020
- Offer price
- $19.00
- Securities offered
- 10,000,000
- Gross proceeds
- $190.00M
- Exchange
- Nasdaq
- First trading day
- Oct 1, 2020
- First-day close
- $39.31+106.9%
- Lock-up ends (est.)
- Mar 30, 2021
“The initial public offering price per share of our common stock is $19.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 296 full time employees, with 229 employees in the U.S., 56 in Europe, and 11 in Asia Pacific.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 1, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 24, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Feb 7, 2012 | Name change | Name changed from PULMONX to Pulmonx Corp |
See a number that looks wrong?